Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00470)
Name
Nimodipine
Synonyms    Click to Show/Hide the Synonyms of This API
nimodipine; 66085-59-4; Nimotop; Periplum; Nimodipino; BAY e 9736; Nimodipinum; Nimodipinum [INN-Latin]; Nimodipino [INN-Spanish]; Bay-E 9736; Bay-e-9736; Nimodipine-d7; CHEBI:7575; Nimodipine (Nimotop); C21H26N2O7; MLS000863294; Nymalize; MFCD00153848; NCGC00015714-09; SMR000058300; DSSTox_CID_3370; DSSTox_RID_76998; DSSTox_GSID_23370; NimoGel; DRG-0139; Nimotop(TM); 1246815-36-0; SR-01000075335; NIMOTOP (TN); EINECS 266-127-0; BRN 0459792; NimoVent; Nimodipime,(S); Nimodipine [USAN:USP:INN:BAN]; Nymalize (TN); CAS-66085-59-4; EG-1961; Opera_ID_14; PubChem16211; Spectrum_001880; SpecPlus_000716; Nimodipine (USP/INN); Prestwick0_000918; Prestwick1_000918; Prestwick2_000918; Prestwick3_000918; Spectrum2_001562; Spectrum3_000766; Spectrum4_000791; Spectrum5_001687; CBiol_001832; Lopac0_000891; SCHEMBL34041; BSPBio_000796; BSPBio_001397; BSPBio_002412; KBioGR_000117; KBioGR_001262; KBioSS_000117; KBioSS_002408; MLS000069381; MLS001076550; MLS001424155; MLS002154061; MLS002172461; MLS003899190; DivK1c_006812; SPECTRUM1503600; SPBio_001464; SPBio_002985; BPBio1_000876; GTPL2523; CHEMBL3197349; DTXSID5023370; SCHEMBL22882841; KBio1_001756; KBio2_000117; KBio2_002403; KBio2_002685; KBio2_004971; KBio2_005253; KBio2_007539; KBio3_000233; KBio3_000234; KBio3_001632; 3-isopropyl 5-(2-methoxyethyl); BRD8407; Bio1_000118; Bio1_000607; Bio1_001096; Bio2_000117; Bio2_000597; HMS1361F19; HMS1570H18; HMS1791F19; HMS1922E04; HMS1989F19; HMS2052M05; HMS2089H13; HMS2093G11; HMS2097H18; HMS2234B05; HMS3262D04; HMS3266O22; HMS3369G07; HMS3394M05; HMS3402F19; HMS3411I12; HMS3657I03; HMS3675I12; HMS3714H18; Pharmakon1600-01503600; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; ACT02628; ALBB-015317; BCP21152; BRD-8407; HY-B0265; 2,6-dimethyl-4-(3-nitrophenyl)-; Nimotop; BAY-e 9736; Tox21_110202; Tox21_500891; BBL028286; BDBM50101971; CA-211; CCG-39340; NSC758476; STK642934; AKOS005174934; AKOS015852459; Nimodipine - CAS 66085-59-4; Tox21_110202_1; AC-8484; CCG-101085; DB00393; KS-1304; LP00891; MCULE-4717687158; NC00335; NSC-758476; SDCCGSBI-0050866.P004; IDI1_033867; NCGC00015714-04; NCGC00015714-05; NCGC00015714-06; NCGC00015714-07; NCGC00015714-08; NCGC00015714-10; NCGC00015714-11; NCGC00015714-12; NCGC00015714-13; NCGC00015714-16; NCGC00015714-28; NCGC00021456-02; NCGC00024675-02; NCGC00024675-03; NCGC00024675-04; NCGC00024675-05; NCGC00024675-06; NCGC00024675-07; NCGC00024675-08; NCGC00024675-09; NCGC00261576-01; SMR002530605; ST082783; SBI-0050866.P003; AB0012346; AB00513963; EU-0100891; FT-0602600; SW219238-1; C07267; D00438; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-; AB00053314-03; AB00053314-04; AB00053314_05; AB00053314_06; 085N594; Q421429; SR-01000075335-1; SR-01000075335-2; SR-01000075335-4; SR-01000075335-5; SR-01000075335-7; BRD-A58048407-001-06-3; BRD-A58048407-001-09-7; BAY E 9736 pound>> BAY-E-9736 pound>> BAYE97; Nimodipine, British Pharmacopoeia (BP) Reference Standard; Nimodipine, European Pharmacopoeia (EP) Reference Standard; Nimodipine, United States Pharmacopeia (USP) Reference Standard; Nimodipine, Pharmaceutical Secondary Standard; Certified Reference Material; Nimodipine for peak identification, EuropePharmacopoeia (EP) Reference Standard
Clinical Status
Approved
Disease Indication Cerebral vasospasm ICD-11: BA85 [1]
PubChem CID
4497
Formula
C21H26N2O7
Canonical SMILES
CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
InChI
1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
InChIKey
UIAGMCDKSXEBJQ-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=4497"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 418.4 Topological Polar Surface Area 120
XlogP 3.1 Complexity 736
Heavy Atom Count 30 Rotatable Bond Count 9
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 8
Full List of Drug Formulations (DFMs) Containing This API
          Nimodipine 30 mg capsule Click to Show/Hide the Full List of Formulation(s):          7 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
D&c yellow no. 10; Butyl alcohol; Isopropyl alcohol; Ammonia; Ferrosoferric oxide; Glycerin; Glycerin; Propylene glycol; Titanium dioxide; Water; Water; Medium-chain triglycerides; Alcohol; Gelatin; Peppermint oil; Polyethylene glycols; Shellac
                   Dosage Form Oral Capsule
                   Company Caraco Pharmaceutical Laboratories
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Quinoline yellow WS DIG Info Estrogen receptor alpha (IC50 = 18 uM) [2]
Isopropyl alcohol DIG Info Lymphoma P388/ADR cells (IC50 = 0.22 uM) [3]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [4]
Medium-chain triglyceride DIG Info Colon cancer Caco-2 cells (Inhibition ratio > 36 %) [5]
             Drug Formulation 2 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c yellow no. 6; Sorbitol; Ammonia; Ferrosoferric oxide; Glycerin; Propylene glycol; Titanium dioxide; Medium-chain triglycerides; Polyethylene glycol 400; Gelatin; Peppermint oil; Polyvinyl acetate phthalate
                   Dosage Form Oral Capsule
                   Company Barr Laboratories
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Sunset yellow FCF DIG Info Solute carrier SLCO2B1 (Ki = 68.4 uM) [6]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [4]
Medium-chain triglyceride DIG Info Colon cancer Caco-2 cells (Inhibition ratio > 36 %) [5]
Polyethylene glycol 400 DIG Info Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) [4]
             Drug Formulation 3 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c red no. 40; Butyl alcohol; Glycerin; Propylene glycol; Titanium dioxide; Water; Polyethylene glycol 400; Alcohol; Gelatin; Light mineral oil; Peppermint oil; Shellac
                   Dosage Form Oral Capsule
                   Company ANI Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Allura red AC dye DIG Info Solute carrier SLCO2B1 (Ki = 4.7 uM) [2]
Allura red AC dye DIG Info Solute carrier SLCO2B1 (Ki = 2.59 uM) [6]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [4]
Polyethylene glycol 400 DIG Info Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) [4]
             Drug Formulation 4 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
D&c yellow no. 10; Butyl alcohol; Ammonia; Ferrosoferric oxide; Glycerin; Titanium dioxide; Water; Medium-chain triglycerides; 1,3-dichloro-2-propanol; Alcohol; Ammonium laureth-5 sulfate; Gelatin; Peppermint oil; Shellac
                   Dosage Form Oral Capsule
                   Company Cardinal Health
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Quinoline yellow WS DIG Info Estrogen receptor alpha (IC50 = 18 uM) [2]
Medium-chain triglyceride DIG Info Colon cancer Caco-2 cells (Inhibition ratio > 36 %) [5]
             Drug Formulation 5 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Mannitol; Sorbitol; Ferrosoferric oxide; Glycerin; Propylene glycol; Titanium dioxide; Gelatin, unspecified; Hypromellose, unspecified; Peppermint oil; Polyethylene glycol, unspecified
                   Dosage Form Oral Capsule
                   Company Cardinal Health
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [7]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [4]
             Drug Formulation 6 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Mannitol; Sorbitol; Ferrosoferric oxide; Glycerin; Propylene glycol; Titanium dioxide; Gelatin; Hypromelloses; Peppermint oil; Polyethylene glycols
                   Dosage Form Oral Capsule
                   Company Bionpharma; Golden State Medical Supply; Heritage
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Mannitol DIG Info Glycine receptor alpha-1 (EC50 = 12589.25 nM) [7]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [4]
             Drug Formulation 7 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Ferrosoferric oxide; Glycerin; Titanium dioxide; Water; Polyethylene glycol 400; Gelatin; Peppermint oil
                   Dosage Form Oral Capsule
                   Company American Health Packaging; Ascend Laboratories; Major Pharmaceuticals; McKesson
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Polyethylene glycol 400 DIG Info Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) [4]
References
1 FDA label for approved nimodipine from the official website of the U.S. Food and Drug Administration.
2 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
3 Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein. J Med Chem. 2004 Mar 11; 47(6):1413-22.
4 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
5 Interactions between human multidrug resistance related protein (MRP2; ABCC2) and excipients commonly used in self-emulsifying drug delivery systems (SEDDS). Int J Pharm. 2013 Apr 15;447(1-2):192-8.
6 Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16009-16018.
7 Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.